Testing targeted and immunotherapy before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed early-stage non-small cell lung cancer (stages IB to IIIB with specific limits).
- Your tumor test shows at least one specific marker, like ALK/ROS1/NTRK fusion, BRAF V600, RET fusion, PD-L1 (at least 1%), or KRAS G12C.
- Your scans show a tumor that can be fully removed with surgery (your surgeon must confirm this).
- You are healthy enough for surgery: breathing and heart function are adequate, and your activity level is good (ECOG 0–1).
- You have no prior treatment for lung cancer in the last 2 years, and no other recent investigational treatment for any condition.
- Screening blood tests for hepatitis B and C are negative (with specific allowed exceptions), and you are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests two medicines given before lung cancer surgery: benmelstobart (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted therapy that stops blood vessel growth to tumors). The goal is to see if they make the cancer disappear completely by the time of surgery.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.